KMT2E and cervical carcinoma: ‏The results suggest that CRISPR/Cas9 targeting of E6 and MLL5 genes can increase‎ apoptotic effects of Cisplatin and can be considered as a potential combination therapy for the treatment of HPV-‎related cervical cancer.